Earlier research shows that torque teno virus (TTV) viral load (VL) is associated with acute rejection and the risk for infection during the 2 years following a solid organ transplant, making it a potential indicator of immunosuppression. Achieving steady-state TTV VL may take 2 months after altering immunity with tacrolimus (TAC), so researchers examined how TTV VL correlates with cellular and humoral immune system status before and after that 2-month time point.
In a single-center, retrospective, pilot study, Justin. P. Rosenheck, DO, and colleagues evaluated immunosuppression with peripheral differential cell counts, peripheral flow automated cytometry (FAC), quantitative immunoglobulins, and TAC dosage and trough level at 1 and 6 months after lung transplant. They also assessed donor-derived cell-free DNA (dd-cfDNA). Participants included 13 lung transplant recipients with a median age of 65 years (range, 61-68) and a male-to-female ratio of 8:5.
Analyses showed that TTV VL increased 100-fold between 1 and 6 months after lung transplant, as participants’ immunity rebounded from immunosuppression. TTV VL was inversely correlated with dd-cfDNA percentage (P=0.002) and was not significantly associated with lymphocytes or cell subsets. The researchers noted no significant associations with FAC lymphocyte subclasses or total immunoglobulin G levels.
In addition, TTV VL was modestly associated with overall TAC trough levels but not TAC dose. According to the researchers, suboptimal TAC levels allow heightened immune activation and molecular injury.
“The inverse relationship of TAC with TTV VL suggests, if further validated, that TTV VL may have value as personalized medicine for risk modulation due to IS [immunosuppression] post LT [lung transplant],” the authors wrote in conclusion.